Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 49-57

  Nadkarni, Anagha ^a   Kalsekar, Iftekhar ^a   You, Min ^a   Forbes, Robert ^b   Hebden, Tony ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adjunctive therapy; Atypical antipsychotics; Depression

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE;

ADULT; ARTICLE; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT CARE; PATIENT SELECTION; RETROSPECTIVE STUDY;

EID: 84873137611     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S36526     Document Type: Article

References (26)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274:740-743.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
4. Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment resistant and non-treatment resistant major depressive disorder. Curr Med Res Opin. 2010;26:2475-2484.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
6. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination, and switching strategies. Drugs. 2011;71:43-64.
7. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.
8. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
9. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22:363-373.
10. Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63:717-726.
11. Russell JM, Hawkina K, Ozminkowski RH, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
12. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16: 370-377.
13. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington: American Psychiatric Publishing; 2010.
14. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66 Suppl 8:13-21.
15. Papakostas GE, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep. 2008;10:481-486.
16. Jing Y, Kalsekar I, Curkendall SM, et al. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. Clin Ther. 2011;33:1246-1257.
17. IMS Health. IMS RxBenchmark: PharMetrics Integrated Database. Available from: http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=d6952a2e23264310VgnVCM100000ed152ca2RCRD&vgnextchannel=c03c90916e442310VgnVCM100000ed152ca2RCRD. Accessed September 20, 2012.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
19. Ashcraft ML, Fries BE, Nerenz DR, et al. A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care. 1989;27:543-557.
20. Petersen T, Papakostas GE, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25:336-341.
21. Bristol-Myers Squibb. Abilify (aripiprazole) [package insert]. Princeton: Bristol-Myers Squibb; 2011.
22. Eli Lilly. Zyprexa (olanzapine) [package insert]. Indianapolis: Eli Lilly; 2011.
23. AstraZeneca. Seroquel (quetiapine) [package insert]. Wilmington: AstraZeneca; 2011.
24. Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012;46:642-649.
25. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatr Serv. 2009;60:1175-1181.
26. Broder MS, Bates JA, Jing Y, Hebden T, Forbes RA, Chang E. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. J Med Econ. 2012;15:105-111.